Michael W. Kalb - 10 May 2023 Form 4 Insider Report for IMPEL PHARMACEUTICALS INC

Role
CFO
Signature
/s/ Adrian Adams as attorney-in-fact
Issuer symbol
N/A
Transactions as of
10 May 2023
Net transactions value
$0
Form type
4
Filing time
12 May 2023, 16:41:42 UTC
Previous filing
24 Feb 2023
Next filing
03 Jan 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IMPL Stock Option (right to buy) Award $0 +175,000 $0.000000 175,000 10 May 2023 Common Stock 175,000 $2.43 Direct F1
transaction IMPL Restricted Stock Units (RSUs) Award $0 +47,500 $0.000000 47,500 10 May 2023 Common Stock 47,500 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests as to 25% of the total shares on May 10, 2024 and then 1/48th of the total shares vests on each monthly anniversary thereafter, subject to the reporting person's provision of service to the issuer on each vesting date.
F2 Each RSU represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement.
F3 The RSUs vest as to 100% of the total shares on May 31, 2024, subject to the reporting person's continuation of employment on such vesting date.